OSE Immunotherapeutics has been granted a patent for a method to manufacture a scalable peptide emulsion for pharmaceutical use. The process involves emulsifying peptides under low shear conditions with adjuvants, resulting in a ready-to-use product meeting sterile product requirements. GlobalData’s report on OSE Immunotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on OSE Immunotherapeutics, Personalized cancer vaccines was a key innovation area identified from patents. OSE Immunotherapeutics's grant share as of May 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11981713B2) discloses a novel ready-to-use emulsion obtained through a specific process involving the emulsification of a peptide suspension under low shear conditions. The emulsion, characterized by a D50 of 10±2 µm, contains a unique combination of peptides and adjuvants, ensuring its stability and efficacy. The method excludes high-speed mixing above 7000 rpm, emphasizing the importance of controlled conditions for optimal results.
The patent further details the composition of the emulsion, highlighting the use of specific adjuvants such as hydrocarbon oils and water-in-oil emulsifiers. The weight ratio of adjuvant to peptide suspension, ranging from 10:1 to 1:1, plays a crucial role in the formulation's properties. Additionally, the patent outlines methods for preparing the peptide suspension and adjusting its pH, ensuring consistency in the final product. The emulsion's application in treating cancer, particularly in subjects expressing the HLA-A2 receptor, is also disclosed, with potential combinations with various therapies for enhanced efficacy. Overall, the patent provides a comprehensive insight into a novel emulsion formulation with promising therapeutic potential in cancer treatment.
To know more about GlobalData’s detailed insights on OSE Immunotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
